A Postmarketing Study of Lecanemab for the Treatment of Participants With Alzheimer's Disease

Summary

The primary purpose of this study is to evaluate the safety of lecanemab-irmb in the real-world clinical setting as reported by events of amyloid-related imaging abnormalities (ARIA)-edema (ARIA-E), ARIA-hemosiderin deposition (ARIA-H), symptomatic ARIA-E, symptomatic ARIA-H, and intracerebral hemorrhage (ICH) greater-than 1 cm in participants treated with lecanemab-irmb. The secondary purpose of this study is to: Evaluate the safety of lecanemab-irmb in the real-world clinical setting as reported by events of seizures, anaphylaxis, central nervous system (CNS) ischemic event, and death.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Alzheimer's Disease

Eligibility basics and study details

Study type

Observational

Phase

Not applicable

Ages

Any age

Sex

All

Healthy volunteers

Not accepted

Sponsor

Eisai Inc.

Last updated on ClinicalTrials.gov

September 16, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites